The authors report a case of an HIV type-1-infected patient concomitantly using highly active antiretroviral therapy and acenocoumarol anticoagulant for secondary prevention of recurrent venous thromboembolism. This is the first report of a possible drug interaction between efavirenz and atazanavir/ritonavir with acenocoumarol and also of the uncomplicated concurrent use of raltegravir with acenocoumarol.
The treatment of individuals infected with HIV type-1 (HIV-1) with highly active antiretroviral therapy (HAART) has significantly advanced over the past 15 years, resulting in an improved lifetime expectancy. The clinical management of HIV-1-infected patients with comorbidities who receive HAART and concomitant medication might be complicated by possible drug-drug interactions. Here, we describe a patient who sequentially used several different HAART regimens while concomitantly using acenocoumarol anticoagulation for secondary prevention of recurrent venous thromboembolism.
Case report
A 51-year-old HIV-1-infected male from the Netherlands was diagnosed with AIDS in October 2003 based on a Pneumocystis jiroveci pneumonia. In November 2006, while being treated for his HIV-1 infection with didanosine (ddI) 400 mg once daily, and fixed-dose lamivudine (3TC) 150 mg and zidovudine 300 mg twice daily, the patient experienced a pulmonary thromboembolism. He was treated with acenocoumarol for 6 months. In March 2007, the patient changed to a less toxic and simpler HAART regimen, consisting of fixed-dose emtricitabine 200 mg, tenofovir disoproxil fumarate 245 mg and efavirenz (EFV) 600 mg once daily. At 3 months after withdrawal of anticoagulant therapy, the patient experienced recurrent venous thromboembolism, associated with presence of lupus coagulant, necessitating lifelong anticoagulation for secondary prevention. No other underlying associated disorders were identified. The use of EFV resulted in an increase of the average daily acenocoumarol dose from 4.2 mg/day (February 2007) to 6.7 mg/day (June 2008), which was needed to achieve target International Normalized Ratio (INR; target 2.5-3.5) values. Assuming interactions with HAART components, the regimen was changed several times: EFV was initially replaced by atazanavir/ritonavir (ATV/RTV) 300/100 mg once daily in July 2008, which led to an increase of the required acenocoumarol average dose to 8.3 mg/day. Thereafter, ATV/RTV was replaced by the integrase inhibitor raltegravir (RAL) 400 mg twice daily in September 2008, INR increased up to 5.7, upon which the acenocoumarol dosage was gradually decreased to approximately 6.4 mg/day. Figure 1 depicts the changes in HAART regimens over time, the average daily acenocoumarol dose (mg/day) and the INR values measured. During this episode, adequate patient adherence to therapy was maintained and HIV-1 plasma viral load remained below the limit of detection, with a single exception in March 2008 (HIV-1 RNA 62 copies/ml).
Discussion
Acenocoumarol is an orally administered vitamin K antagonist, indirectly inhibiting coagulation. Because of 
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high interpatient variability in response, dosages have to be adjusted based on regular INR or prothrombin measurements. Cytochrome P450 (CYP)2C9 enzyme is responsible for the greatest part of the metabolism of both the R-and S-enantiomers of acenocoumarol. Active R-acenocoumarol is also metabolized by CYP1A2, 2C19 and 3A4 enzymes [1] . The S-enantiomer has a very short half-life; therefore, only R-acenocoumarol provides a pharmacological effect in vivo [1, 2] . Data on possible drug interactions between HAART and acenocoumarol has been limited to three case reports, summarized in Table 1 [3] [4] [5] . In the US, warfarin, rather than acenocoumarol, is the most widely used oral anticoagulant. Contrary to acenocoumarol, the S-enantiomer of warfarin (metabolized primarily by CYP2C9) is five times more potent than the R-enantiomer (metabolized by several enzymes including CYP1A2, CYP2C19 and CYP3A4) [6] . Over the past years several cases of possible interactions between HAART and warfarin have been described [6] . Interactions expected between acenocoumarol and HAART regimens are mainly based on theoretical assumptions and case reports about similar drugs like warfarin, but these might not be fully applicable to acenocoumarol. The common pathway of CYP2C9 in the metabolism of R-acenocoumarol and S-warfarin, however, suggests that, at least partly, extrapolations can be made. This is the first case report describing the concomitant use of EFV with acenocoumarol. In vitro studies show that EFV inhibits CYP2C9 [7] . In vivo, EFV might be a CYP2C9 inducer; the higher dose of acenocoumarol that was needed in our patient is in line with CYP2C9 induction [7] . Our experience with the combination of EFV and acenocoumarol contrasts with the report by Bonora et al. [8] , who reported increased INR during concomitant use of warfarin and ddI, 3TC and EFV, suggesting inhibition of CYP2C9 by EFV as the causal mechanism. It is also possible that initial doses of EFV might lead to CYP2C9 inhibition, but that after repeated administration the net effect on CYP2C9 is induction. Interindividual variability in the metabolism of anticoagulants could also be caused by the presence of different variant VKORC1 and CYP2C9 alleles in these individual cases.
RTV is known to be a potent inhibitor of enzymes CYP3A and CYP2D6, hence its use as a booster in combination with other protease inhibitors. However, RTV can also induce the glucuronidation by UDPglucuronyltransferases and the oxidation by CYP1A2, CYP2C8, CYP2C9 and CYP2C19 [9] . The induction of CYP1A2 and CYP2C9 activity by RTV might lead to an extensive metabolization of R-acenocoumarol and hence the need for a higher dose of acenocoumarol [3] . ATV/RTV use in combination with warfarin has been reported to cause a decrease, and less often, an increase in the INR [10] . In this combination of drugs the metabolic profile of RTV overpowers that of ATV; thus, the induction of CYP1A2 and CYP2C9 by RTV probably resulted in higher dosages of acenocoumarol needed to achieve the target INR. RAL is not an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A, nor an inductor of CYP3A4, nor an inhibitor of UDP-glucuronosyltransferases 1A1 and 2B7, nor an inhibitor of P-glycoprotein regulated transport [11] . Therefore, theoretically, it should not affect the metabolism of acenocoumarol (or warfarin). The lack of possible interactions and its proven efficacy in both treatment-naive and treatment-experienced patients makes it an interesting drug to be used in combination with other medication. The treatment of HIVinfected patients with significant comorbidity is still an area in which physicians lack extensive experience. Hopefully this can be improved by sharing significant observations by publication as case reports or case series, as formal interaction studies are often lacking. The possibility of measuring an INR at least provides an objective demonstration of what effect a certain change has on the coagulation.
In the present case report, plasma levels of antiretroviral drugs were not measured; therefore, there is no data available to discuss the effects of acenocoumarol on the effectiveness of the different HAART regimens. Reassuringly, viral load remained undetectable over time (with the exception of a single blip), despite the various changes in the HAART regimens. Errors in INR measurements, non-adherence, interaction with other comedication, use of vitamin K, comorbidity, genetic factors (CYP2C9 and VKORC1 polymorphism), improved liver function and hypothyroidism have been examined, and as far as possible been ruled out as potential confounders.
Conclusions
This is the first report of a possible clinical interaction between EFV and ATV/RTV with acenocoumarol, and of the uncomplicated concurrent use of RAL with acenocoumarol. In HIV-1-infected patients who require the chronic concurrent use of acenocoumarol and HAART, physicians should be aware of sub-or supratherapeutic anticoagulation caused by possible drug-drug interactions. Its theoretical metabolic profile, lack of interactions and proven effectiveness renders RAL an attractive candidate when drug interactions might pose a problem. Further prospective studies are required to confirm our observation.
